Inhibition of Jun NH2-Terminal Kinases Suppresses the Growth of Experimental Head and Neck Squamous Cell Carcinoma

Purpose: This study was carried out to investigate whether c-Jun NH2-terminal kinases (JNK) are potential targets for treating head and neck squamous cell carcinoma (HNSCC). Experimental Design: JNK activity was first evaluated in 20 paired samples of human HNSCC. The antitumor activity of SP600125, a reversible nonselective ATP-competitive inhibitor of JNKs, was then investigated both in an HNSCC xenograft model and in vitro using immunohistochemistry, immunoblotting, enzyme immunoassay, flow cytometry, and a Matrigel assay of capillary tube formation. Complementary studies were carried out using small interfering RNA to JNK1/2. Results: JNK activity was increased in human HNSCC compared with normal-appearing epithelium. Treatment of mice bearing HNSCC xenografts with SP600125 resulted in >60% inhibition of tumor growth relative to vehicle-treated animals. Inhibition of tumor growth was associated with significant reductions in both cell proliferation and microvessel density. SP600125 inhibited tumor cell proliferation by causing delays in both the S and G2-M phases of the cell cycle. Inhibition of angiogenesis seemed to reflect effects on both tumor and endothelial cells. The JNK inhibitor suppressed the production of vascular endothelial growth factor and interleukin-8 by tumor cells and also inhibited endothelial cell proliferation and capillary tube formation. Reduced amounts and phosphorylation of epidermal growth factor receptor were found in tumor cells after treatment with SP600125. Small interfering RNA–mediated suppression of JNK1/2 led to reduced tumor cell proliferation and decreased levels of epidermal growth factor receptor, vascular endothelial growth factor, and interleukin-8. Conclusions: JNK activity is commonly increased in HNSCC. Our preclinical results provide a rationale for evaluating JNK inhibition as an approach to treating HNSCC.

[1]  L. Vassilev,et al.  Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1 , 2007, Oncogene.

[2]  J. Pollack,et al.  c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells , 2007, Oncogene.

[3]  N. Kamata,et al.  Expression of E-cadherin in oral cancer cell lines and its relationship to invasiveness in SCID mice in vivo. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[4]  J. Grandis,et al.  Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Namba,et al.  Selective pharmacologic inhibition of c-Jun NH2-terminal kinase radiosensitizes thyroid anaplastic cancer cell lines via induction of terminal growth arrest. , 2006, Thyroid : official journal of the American Thyroid Association.

[6]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[7]  S. Katsuno,et al.  Differences in the expression of genes between normal tissue and squamous cell carcinomas of head and neck using cancer-related gene cDNA microarray , 2006, Acta oto-laryngologica.

[8]  M. Shah,et al.  Targeting the cell cycle: a new approach to cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Thomas C. Chen,et al.  Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells. , 2005, Cancer research.

[10]  J. Greenwood,et al.  Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  S. Eichhorst,et al.  Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. , 2005, Cancer research.

[12]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[13]  C. Tournier,et al.  Selective Regulation of c-jun Gene Expression by Mitogen-Activated Protein Kinases via the 12-O-Tetradecanoylphorbol-13-Acetate- Responsive Element and Myocyte Enhancer Factor 2 Binding Sites , 2005, Molecular and Cellular Biology.

[14]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. K. Bilter,et al.  Inhibition of Tumor Growth, Angiogenesis, and Tumor Cell Proliferation by a Small Molecule Inhibitor of c-Jun N-terminal Kinase , 2005, Journal of Pharmacology and Experimental Therapeutics.

[16]  I. Kawase,et al.  Cigarette smoke extract induces endothelial cell injury via JNK pathway. , 2005, Biochemical and biophysical research communications.

[17]  C. Cordon-Cardo,et al.  Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism , 2005, Clinical Cancer Research.

[18]  C. Lyle,et al.  Inhibition of Cell Proliferation and Cell Cycle Progression by Specific Inhibition of Basal JNK Activity , 2004, Journal of Biological Chemistry.

[19]  S. Takashiba,et al.  C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect. , 2003, Transplantation.

[20]  Paul Dent,et al.  MAPK pathways in radiation responses , 2003, Oncogene.

[21]  E. Wagner,et al.  c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. , 2003, Developmental cell.

[22]  J. Bonventre,et al.  Stretch-induced IL-8 depends on c-Jun NH2-terminal and nuclear factor-kappaB-inducing kinases. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[23]  O. Kozawa,et al.  Involvement of SAPK/JNK in basic fibroblast growth factor-induced vascular endothelial growth factor release in osteoblasts. , 2003, The Journal of endocrinology.

[24]  Michelle L. Varney,et al.  IL-8 Directly Enhanced Endothelial Cell Survival, Proliferation, and Matrix Metalloproteinases Production and Regulated Angiogenesis1 , 2003, The Journal of Immunology.

[25]  D. Bar-Sagi,et al.  Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. , 2003, Genes & development.

[26]  C. Cordon-Cardo,et al.  Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  C. Cordon-Cardo,et al.  Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  J. Baselga,et al.  Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. , 2001, Cancer research.

[29]  N. Holbrook,et al.  Protective Role for c-Jun in the Cellular Response to DNA Damage* , 2001, The Journal of Biological Chemistry.

[30]  A. Adjei,et al.  Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.

[31]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[32]  N. Colburn,et al.  Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Muschel,et al.  Radiosensitivity and the cell cycle. , 1999, The cancer journal from Scientific American.

[34]  E. Levin,et al.  Extracellular Signal-regulated Protein Kinase/Jun Kinase Cross-talk Underlies Vascular Endothelial Cell Growth Factor-induced Endothelial Cell Proliferation* , 1998, The Journal of Biological Chemistry.

[35]  Y. Ip,et al.  Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. , 1998, Current opinion in cell biology.

[36]  O. Potapova,et al.  The Jun Kinase/Stress-activated Protein Kinase Pathway Functions to Regulate DNA Repair and Inhibition of the Pathway Sensitizes Tumor Cells to Cisplatin* , 1997, The Journal of Biological Chemistry.

[37]  D. Sidransky,et al.  p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. , 1996, Cancer research.

[38]  P. Sacks.  Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck , 1996, Cancer and Metastasis Reviews.

[39]  M. Karin.  The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases (*) , 1995, The Journal of Biological Chemistry.

[40]  P. Chambon,et al.  Modulation by retinoic acid (RA) of squamous cell differentiation, cellular RA-binding proteins, and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. , 1994, Cancer research.

[41]  J. Mcdonald,et al.  Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. , 1994, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[42]  Z. Dong,et al.  Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Pathak,et al.  Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. , 1988, Cancer research.

[44]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[45]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[46]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[47]  Horng-mo Lee,et al.  Hyperbaric oxygen induces VEGF expression through ERK, JNK and c-Jun/AP-1 activation in human umbilical vein endothelial cells. , 2006, Journal of biomedical science.

[48]  E. Wagner,et al.  Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. , 2006, The international journal of biochemistry & cell biology.

[49]  J. Rhim,et al.  C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  C. Miller,et al.  Developmental expression in the mouse nervous system of the p493F12 SAP kinase. , 1996, Brain research. Molecular brain research.